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Objectives
Before initiating an antiretroviral combination therapy
which includes Maraviroc as one of its components, a
coreceptor tropism test has to be performed. As Mara-
viroc is only effective against HIV strains that are using
CCR5 as coreceptor a thoroughly validated and reliable
assay should be performed. In case of treatment change
due to toxicity, testing should also be possible using
proviral DNA.
Material and methods
Included in the study cohort of this non-interventional
observational study are 157 patients. Only inclusion
criteria was a treatment with Maraviroc and a previous
tropism test. Phenotypic tropism tests were performed
by Monogram biosciences (TROFILE®). For Genotypic
tropism determination from V3 loop sequence data
geno2pheno[coreceptor]* was used. Data acquisition for
week 12 and week 24 is already finished. It is planned
to collect data for 96 weeks for all the patients. Data
analysed are besides viral load and the other compo-
nents of the HAART, genotypic resistance assay at
baseline, immunologic parameters and treatment side
effects.
Results
Genotypic tropism results were available for 88 patients
from viral RNA sequences and for 53 patients from pro-
viral DNA sequences. A TROFILE® result was available
for 70 of the patients as 71 of the patients had a viral
load below 1000 cop./ml and a testing with TROFILE®
was not possible. In the intent to treat (ITT) analysis
70% of the patients were successfully treated at week 24,
defined as a viral load decline of at least 3 logs or a viral
load below detection limit of 50 copies/ml. The positive
predictive value (PPV) of geno2pheno using a FPR cut-
off of 10% was 77% (PPV TROFILE®: 66%). In the sub-
group of patients where only a genotypic tropism test
from proviral DNA was available 86% of the patients
had a viral load below detection limit of 50 copies/ml
(70% at baseline).
Conclusions
On this clinical dataset performance in terms of predic-
tive power is slightly better when using geno2pheno
compared to TROFILE®. Therefore genotypic tropism
testing proves to be an easy and inexpensive alternative
to phenotypic tropism testing.
Especially in the group of patients, where only a geno-
typic tropism test could be performed from proviral
DNA, a high rate of successful treatments was observed,
showing that this method makes it possible to perform
tropism testing guided treatment change despite unde-
tectable viral load.
*geno2pheno[coreceptor]: http://www.geno2pheno.org
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